Bingham Osborn & Scarborough LLC boosted its stake in Merck & Company, Inc. (NYSE:MRK) by 0.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,210 shares of the company’s stock after acquiring an additional 2 shares during the period. Bingham Osborn & Scarborough LLC’s holdings in Merck & were worth $398,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in MRK. Canada Pension Plan Investment Board boosted its holdings in Merck & by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after acquiring an additional 2,300,200 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Merck & by 23.7% in the first quarter. AQR Capital Management LLC now owns 8,146,594 shares of the company’s stock valued at $517,635,000 after acquiring an additional 1,561,853 shares in the last quarter. Karp Capital Management Corp bought a new stake in Merck & in the first quarter valued at $94,200,000. CIBC World Markets Inc. boosted its holdings in Merck & by 536.0% in the first quarter. CIBC World Markets Inc. now owns 1,290,373 shares of the company’s stock valued at $81,990,000 after acquiring an additional 1,087,497 shares in the last quarter. Finally, Independent Franchise Partners LLP boosted its holdings in Merck & by 12.4% in the second quarter. Independent Franchise Partners LLP now owns 9,250,317 shares of the company’s stock valued at $592,852,000 after acquiring an additional 1,020,630 shares in the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Merck & Company, Inc. (MRK) Position Increased by Bingham Osborn & Scarborough LLC” was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.com-unik.info/2017/10/31/merck-company-inc-mrk-position-increased-by-bingham-osborn-scarborough-llc.html.
Merck & Company, Inc. (MRK) opened at 54.71 on Tuesday. The company has a 50-day moving average of $63.99 and a 200-day moving average of $63.61. Merck & Company, Inc. has a 52 week low of $54.41 and a 52 week high of $66.80. The company has a market cap of $149.21 billion, a PE ratio of 29.62 and a beta of 0.80.
Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The company’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the company earned $1.07 earnings per share. On average, equities analysts expect that Merck & Company, Inc. will post $3.89 EPS for the current year.
MRK has been the topic of several recent analyst reports. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $74.00 price target (up previously from $70.00) on shares of Merck & in a report on Thursday, July 27th. Citigroup Inc. set a $65.00 target price on shares of Merck & and gave the company a “hold” rating in a report on Wednesday, July 5th. BMO Capital Markets set a $70.00 target price on shares of Merck & and gave the company a “buy” rating in a report on Wednesday, October 11th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “sell” rating and set a $55.00 target price on shares of Merck & in a report on Friday, October 20th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. Merck & presently has an average rating of “Hold” and an average price target of $67.53.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.